S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
NASDAQ:BLUE

bluebird bio - BLUE News Today

$5.81
-0.97 (-14.31%)
(As of 08/18/2022 05:45 PM ET)
Add
Compare
Today's Range
$5.50
▼
$7.20
50-Day Range
$3.06
▼
$6.83
52-Week Range
$2.87
▼
$25.39
Volume
30.89 million shs
Average Volume
5.04 million shs
Market Capitalization
$448.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.27
Get bluebird bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter.

BLUE Media Mentions By Week

BLUE Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

BLUE
News Sentiment
▼
0.85

0.63
▲
Average
Medical
News Sentiment

BLUE News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

BLUE Articles
This Week
▼
25

3
▲
BLUE Articles
Average Week



SourceHeadline
marketbeat.com logobluebird bio Target of Unusually High Options Trading (NASDAQ:BLUE)
marketbeat.com - August 18 at 11:19 AM
marketbeat.com logobluebird bio (NASDAQ:BLUE) PT Raised to $10.00 at SVB Leerink
marketbeat.com - August 18 at 8:22 AM
finance.yahoo.com logobluebird's (BLUE) Gene Therapy Gets FDA Nod for Beta-Thalassemia
finance.yahoo.com - August 18 at 3:02 PM
nasdaq.com logoBluebird falls on worries over $2.8 mln gene therapy's commercial success
nasdaq.com - August 18 at 3:02 PM
bizjournals.com logo'We are ready to go': bluebird plans for commercial launch of beta thalassemia gene therapy
bizjournals.com - August 18 at 3:02 PM
markets.businessinsider.com logoWhat 4 Analyst Ratings Have To Say About bluebird bio
markets.businessinsider.com - August 18 at 3:02 PM
finance.yahoo.com logoBluebird stock pops after FDA approves its gene therapy drug
finance.yahoo.com - August 18 at 3:02 PM
marketwatch.com logoBluebird Shares Rise After FDA Approval
marketwatch.com - August 18 at 10:01 AM
investing.com logoBluebird Bio Extends Rally as Analysts Reflect Positively on Zynteglo Approval
investing.com - August 18 at 10:01 AM
nasdaq.com logoFDA Approves Bluebird Bio's Gene Therapy For Rare Blood Disease
nasdaq.com - August 17 at 11:59 PM
barrons.com logoFDA Approves Bluebird Bio’s Pricey Gene Therapy
barrons.com - August 17 at 11:59 PM
za.investing.com logobluebird bio's Zynteglo Gets FDA Approval - List Price In-Line Says Analyst
za.investing.com - August 17 at 6:59 PM
msn.com logoBluebird’s Game-Changing Therapy for Rare Blood Disorder Cleared by FDA
msn.com - August 17 at 6:59 PM
markets.businessinsider.com logoBluebird Secures FDA Nod For Genetic Blood Disease Candidate
markets.businessinsider.com - August 17 at 6:59 PM
reuters.com logoBluebird's $2.8 mln gene therapy becomes most expensive drug after U.S. approval
reuters.com - August 17 at 6:59 PM
msn.com logoBluebird Bio’s first gene therapy for rare blood disease wins FDA approval
msn.com - August 17 at 6:59 PM
finance.yahoo.com logoFDA Approves Bluebird’s $2.8 Million Gene Therapy for Rare Blood Disease
finance.yahoo.com - August 17 at 6:59 PM
finance.yahoo.com logobluebird bio (BLUE) Focused on Pipeline Amid Marketed Drug Dearth
finance.yahoo.com - August 16 at 12:19 AM
MarketBeat logobluebird bio (NASDAQ:BLUE) & Vaxart (NASDAQ:VXRT) Critical Review
americanbankingnews.com - August 13 at 1:42 AM
MarketBeat logoInsider Selling: bluebird bio, Inc. (NASDAQ:BLUE) Insider Sells $32,696.72 in Stock
americanbankingnews.com - August 11 at 6:20 AM
MarketBeat logoAndrew Obenshain Sells 21,805 Shares of bluebird bio, Inc. (NASDAQ:BLUE) Stock
americanbankingnews.com - August 10 at 5:38 AM
MarketBeat logobluebird bio (NASDAQ:BLUE) and Aerie Pharmaceuticals (NASDAQ:AERI) Head to Head Analysis
americanbankingnews.com - August 9 at 3:50 AM
MarketBeat logoBarclays Upgrades bluebird bio (NASDAQ:BLUE) to "Equal Weight"
americanbankingnews.com - August 9 at 1:58 AM
seekingalpha.com logoBluebird bio gains as earnings update draws upgrade at Barclays
seekingalpha.com - August 5 at 3:42 PM
finance.yahoo.com logoBluebird Bio (BLUE) Reports Q2 Loss, Lags Revenue Estimates
finance.yahoo.com - August 5 at 12:12 AM
finance.yahoo.com logobluebird bio Reports Second Quarter 2022 Financial Results and Highlights Operational Progress
finance.yahoo.com - August 4 at 7:11 PM
MarketBeat logobluebird bio (NASDAQ:BLUE) Stock Rating Upgraded by Raymond James
americanbankingnews.com - August 4 at 3:51 AM
fool.com logo1 Reason to Buy Bluebird Bio, and 1 Reason to Sell
fool.com - August 3 at 10:59 AM
finance.yahoo.com logoBluebird Bio (BLUE) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
finance.yahoo.com - August 1 at 12:51 PM
finance.yahoo.com logoGlobal T-Cell Immunotherapy Market Report to 2027 - Featuring Atara Biotherapeutics, Autolus and bluebird bio Among Others
finance.yahoo.com - July 21 at 7:55 AM
finance.yahoo.com logoWhat Kind Of Shareholders Hold The Majority In bluebird bio, Inc.'s (NASDAQ:BLUE) Shares?
finance.yahoo.com - July 14 at 9:59 AM
finance.yahoo.com logoBluebird (BLUE) Surges 18%: Is This an Indication of Further Gains?
finance.yahoo.com - July 6 at 3:47 PM
finance.yahoo.com logoWhy Bluebird Bio Stock Is Flying Today
finance.yahoo.com - July 5 at 3:48 PM
finance.yahoo.com logo2 Biotech Stocks That Could Soar in the Third Quarter
finance.yahoo.com - July 2 at 7:21 AM
finance.yahoo.com logoIs Now a Good Time to Buy This Biotech Stock?
finance.yahoo.com - June 23 at 3:51 PM
finance.yahoo.com logoWhy Bluebird Bio Stock Stumbled Today
finance.yahoo.com - June 14 at 5:44 PM
bizjournals.com logoBluebird stock soars on FDA committee news, despite overall market woes
bizjournals.com - June 13 at 4:33 PM
finance.yahoo.com logoAnalysts Consider CRISPR Therapeutics' Blood Disorder Trial Data Encouraging, Impressive
finance.yahoo.com - June 13 at 4:33 PM
finance.yahoo.com logoBluebird Bio Stock Set for Largest One-Day Gain in Eight Years
finance.yahoo.com - June 13 at 4:33 PM
seekingalpha.com logoBluebird bio surges 71% after FDA backing for gene therapies
seekingalpha.com - June 13 at 10:09 AM
finance.yahoo.com logoFDA Advisory Committee Backs Bluebird Bio's Blood Disorder Gene Therapy
finance.yahoo.com - June 13 at 10:09 AM
finance.yahoo.com logobluebird bio (Finally) Nears Approval. What's Next?
finance.yahoo.com - June 13 at 10:09 AM
finance.yahoo.com logoBluebird's stock is up 70% after FDA committee voted in favor of the company's gene therapies last week
finance.yahoo.com - June 13 at 10:09 AM
finance.yahoo.com logoBluebird Bio Stock Set to Soar After FDA Advisers Support Treatments
finance.yahoo.com - June 13 at 10:09 AM
nasdaq.com logoFDA Panel Endorses Bluebird Bio's Beti-cel Gene Therapy For Rare Blood Disease
nasdaq.com - June 11 at 4:50 PM
msn.com logoBluebird Bio stock rises 62%, FDA committee supports treatments
msn.com - June 10 at 8:48 PM
reuters.com logoBluebird bio's gene therapy for blood disorder gets FDA panel backing
reuters.com - June 10 at 8:48 PM
msn.com logoFDA advisory committee unanimous in support of Bluebird Bio’s two gene therapies
msn.com - June 10 at 8:48 PM
bizjournals.com logoIn crucial win, bluebird nabs a second FDA committee endorsement
bizjournals.com - June 10 at 3:48 PM
finance.yahoo.com logoFDA Advisory Committee Unanimously Supports beti-cel Gene Therapy for People with beta-thalassemia Who Require Regular Red Blood Cell Transfusions
finance.yahoo.com - June 10 at 3:48 PM
nasdaq.com logoFDA Panel Endorses Bluebird Bio's Eli-cel Gene Therapy For Rare Neurodegenerative Disease
nasdaq.com - June 10 at 10:48 AM
msn.com logoBluebird’s Brain Disease Therapy Wins FDA Advisers’ Support
msn.com - June 10 at 10:48 AM
Get bluebird bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:BLUE) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.